What is Skin Analytics?
Skin Analytics is a pioneering health-tech enterprise focused on the development of AI as a Medical Device (AIaMD). Its flagship platform, DERM, is engineered to provide dermatologist-quality assessments, effectively bridging the gap between primary care and specialized oncology services. By integrating its proprietary technology into existing health systems, the company aims to improve patient outcomes while simultaneously reducing the operational and financial pressures on healthcare providers. The firm's market position is defined by its commitment to clinical validation and its ability to deliver sustainable, high-efficiency diagnostic pathways that are increasingly essential in modern, resource-constrained medical environments.
How much funding has Skin Analytics raised?
Skin Analytics has raised a total of $26.5M across 4 funding rounds:
Grant
$100K
Corporate Investment
$1.2M
Series A
$5.2M
Series B
$19.9M
Grant (2014): $100K with participation from Founder.org
Corporate Investment (2018): $1.2M led by Bristol Private Equity Club
Series A (2020): $5.2M supported by Nesta Holding Co, Hoxton Ventures, and Mustard Seed Venture INC
Series B (2025): $19.9M featuring Intrepid Partners
Key Investors in Skin Analytics
Intrepid Partners
Intrepid Partners is a specialized consultancy firm providing project management and business advisory services, with a strong focus on financial and regulatory frameworks for diverse industries.
Hoxton Ventures
Hoxton Ventures is a London-based early-stage venture capital firm that targets European technology startups capable of disrupting existing industries and scaling into global market leaders.
Founder.org
Founder.org is a specialized investment and company-building program that supports young entrepreneurs in solving global challenges through high-impact, scalable business models.
What's next for Skin Analytics?
With this latest capital injection, Skin Analytics is well-positioned to accelerate its international expansion and deepen its integration within global health systems. The strategic focus will likely shift toward scaling the deployment of the DERM platform, enhancing its diagnostic accuracy through continuous data refinement, and navigating the complex regulatory landscapes of new markets. As the company moves into this mature growth stage, the emphasis will remain on proving the long-term economic viability of its AI-enabled pathways, ensuring that health systems can provide faster, more accurate skin cancer screenings without compromising on quality or increasing costs. Future efforts will likely involve strategic partnerships with major hospital networks and public health organizations to solidify its footprint as a standard-bearer for AI-driven dermatological care.
See full Skin Analytics company page
